VTYX
Ventyx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.00
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +31.1%
- EBIT
- +29.8%
- EPS
- +36.4%
- Free cash flow
- +45.0%
- Operating cash flow
- +44.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +29.0%
- EBIT
- +28.6%
- Net income
- +30.0%
- EPS
- +40.3%
- Free cash flow
- +21.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2025